<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To estimate prevalence of non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) and its association with <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> (type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (DM), <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e>) and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (MS) in urban south Indians </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This study was carried out in 541 subjects (response rate 92%) of the original sample of 26,001 subjects in the Chennai Urban Rural Epidemiology Study maintaining the representativeness </plain></SENT>
<SENT sid="2" pm="."><plain>Anthropometry and <z:chebi fb="23" ids="18059">lipid</z:chebi> estimations were done in <z:hpo ids='HP_0000001'>all</z:hpo> and oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test in <z:hpo ids='HP_0000001'>all</z:hpo>, except self-reported diabetic subjects </plain></SENT>
<SENT sid="3" pm="."><plain>NAFLD was diagnosed by ultrasonography and MS by modified Adult Treatment Panel III (ATP III) criteria </plain></SENT>
<SENT sid="4" pm="."><plain>DM, <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) and impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (IFG) were defined using WHO consulting group criteria </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Overall prevalence of NAFLD was 32% (173/541 subjects) (men: 35.1%, women: 29.1%, p=0.140) </plain></SENT>
<SENT sid="6" pm="."><plain>Prevalence of most cardio-metabolic risk factors was significantly higher in NAFLD subjects </plain></SENT>
<SENT sid="7" pm="."><plain>Prevalence of NAFLD (54.5%) was higher in subjects with DM compared to those with <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> (IGT or IFG) (33%), isolated IGT (32.4%), isolated IFG (27.3%) and <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT) (22.5%) (DM vs. <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e>: p&lt;0.05, DM vs. NGT: p&lt;0.001, <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> vs. NGT: p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Even after adjusting for age, gender and waist circumference, NAFLD was associated with <z:mp ids='MP_0002055'>diabetes</z:mp> (OR: 2.9, 95% C.I.: 1.9-4.6, p&lt;0.001) and MS (OR: 2.0, 95% C.I.: 1.3-3.1, p&lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: NAFLD is present in a third of urban Asian Indians and its prevalence increases with increasing severity of <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> and in MS </plain></SENT>
<SENT sid="10" pm="."><plain>This is the first population-based prevalence of NAFLD from south Asia which faces the brunt of the <z:mp ids='MP_0002055'>diabetes</z:mp> epidemic </plain></SENT>
</text></document>